<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sirolimus (conventional): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sirolimus (conventional): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Sirolimus (conventional): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11048" href="/d/html/11048.html" rel="external">see "Sirolimus (conventional): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12761" href="/d/html/12761.html" rel="external">see "Sirolimus (conventional): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709411"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Immunosuppression:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Increased susceptibility to infection and the possible development of lymphoma and other malignancies may result from immunosuppression.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Experienced physician:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Only physicians experienced in immunosuppressive therapy and management of renal transplant patients should use sirolimus for prophylaxis of organ rejection in patients receiving renal transplants. Patients receiving sirolimus should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Liver transplantation:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The use of sirolimus in combination with tacrolimus was associated with excess mortality and graft loss in a study in <i>de novo</i> liver transplant patients. Many of these patients had evidence of infection at or near the time of death. In this and another study in <i>de novo </i>liver transplant patients, the use of sirolimus in combination with cyclosporine or tacrolimus was associated with an increase in hepatic artery thrombosis; most cases of hepatic artery thrombosis occurred within 30 days post transplantation, and most led to graft loss or death. The safety and efficacy of sirolimus as immunosuppressive therapy have not been established in liver transplant patients; therefore, such use is not recommended.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Lung transplantation:</span>
<div class="collapsible-wrap">
<p style="text-indent:-4em;margin-left:4em;">Cases of bronchial anastomotic dehiscence, most fatal, have been reported in <i>de novo</i> lung transplant patients when sirolimus has been used as part of an immunosuppressive regimen. The safety and efficacy of sirolimus as immunosuppressive therapy have not been established in lung transplant patients; therefore, such use is not recommended.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F221226"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Rapamune</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868238"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Rapamune</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F221253"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Immunosuppressant Agent;</li>
<li>
                        mTOR Kinase Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F221230"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Refer to the Sirolimus (Protein Bound) monograph for dosing and information related to the IV sirolimus protein-bound formulation. Patient should be under the care of a clinician experienced in immunosuppressive therapy and management of the specific indication.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1cb7458f-9e74-4cdf-aa9c-3f8e12267ad0">Chordoma, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chordoma, advanced: Oral:</b> 2 mg once daily adjusted to maintain a trough level between 15 and 20 ng/mL (in combination with imatinib) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19570961']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19570961'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ee83bdbc-6f57-438d-9ad5-ce26b1ad18ef">Graft-versus-host disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Graft-versus-host disease (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Graft-versus-host disease, prevention:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Typically used in combination with other immunosuppressive therapies; refer to study protocols for further information.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 2 mg once daily initially starting 3 days prior to allogeneic hematopoietic cell transplant and adjusted to maintain trough levels between 3 and 12 ng/mL through day 150, followed by a taper through day 180 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31248843']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31248843'])">Ref</a></span>) or through day 180, followed by a taper through day 365 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32603426']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32603426'])">Ref</a></span>) in the absence of graft-versus-host disease (GVHD) (in combination with cyclosporine and mycophenolate mofetil) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32603426','lexi-content-ref-31248843']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32603426','lexi-content-ref-31248843'])">Ref</a></span>) <b>or </b>12 mg loading dose starting 3 days prior to allogeneic hematopoietic cell transplant, followed by 4 mg daily (target sirolimus trough level: 3 to 12 ng/mL; in combination with tacrolimus ± methotrexate); taper off after 6 to 9 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19001324','lexi-content-ref-17138818']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19001324','lexi-content-ref-17138818'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Graft-versus-host disease, acute, treatment: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Newly diagnosed standard-risk acute graft-versus-host disease: </i>
<b>Oral:</b> 6 mg loading dose, followed by maintenance dosing to maintain a target trough between 10 to 14 ng/mL until resolution of acute GVHD, then titrate dose to a target trough of 5 to 10 ng/mL after resolution of acute GVHD until at least day 56, then taper to discontinue by 3 months from day 56 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31738834']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31738834'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Refractory acute graft-versus-host disease: </i>
<b>Oral:</b> 4 to 5 mg/m<sup>2</sup> for 14 days (no loading dose) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11773890']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11773890'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Graft-versus-host disease, chronic treatment: Oral:</b> 6 mg loading dose, followed by 2 mg daily (target trough level: 7 to 12 ng/mL) for 6 to 9 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16042691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16042691'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="95838855-eaf4-43c1-938a-d8c89e5591fb">Heart transplantation, prophylaxis of rejection and allograft vasculopathy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heart transplantation, prophylaxis of rejection and allograft vasculopathy (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Avoid use in the immediate post–heart transplant period (eg, ≤30 days post transplant) due to risk for adverse effects (eg, impaired wound healing, infection) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36032031']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36032031'])">Ref</a></span>). Dose and target sirolimus trough concentrations must be highly individualized based on time from transplant, assay method, and concurrent therapies. The following are examples of dosing regimens based on the available literature; refer also to institutional protocols:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Calcineurin inhibitor minimization:</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note</b>: With this approach, the antiproliferative (eg, mycophenolate) is typically discontinued. The calcineurin inhibitor (CNI) dose and target trough concentration should be reduced when sirolimus is initiated to reduce the risk of kidney toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36032031']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36032031'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Upon discontinuation of antiproliferative, administer sirolimus 6 mg loading dose followed by 2 mg once daily titrated to target trough concentrations between 4 and 12 ng/mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37080658','lexi-content-ref-12742978']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37080658','lexi-content-ref-12742978'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Calcineurin inhibitor avoidance</b></i>:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note</b>: Conversion from a CNI to sirolimus may be undertaken &gt;1 month post transplant in carefully selected individuals with compelling indications for mTOR inhibitor therapy (eg, CNI toxicity or intolerance) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36032031']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36032031'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Immediate calcineurin inhibitor dose reduction approach: Oral:</b> Reduce cyclosporine by 25 mg twice daily or tacrolimus by 1 mg twice daily, followed by initiation of sirolimus 1 mg once daily. Adjust sirolimus dose to target trough concentrations between 8 and 14 ng/mL; once target trough concentrations achieved, withdraw CNI and repeat biopsy 2 weeks after CNI withdrawal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22207715']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22207715'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Delayed calcineurin inhibitor dose reduction approach:</b>
<b>Oral:</b> Initiate sirolimus 1 mg once daily for 1 week, then adjust sirolimus to target trough concentrations between 10 and 15 ng/mL over the following 2 weeks. Once sirolimus target trough concentrations achieved, reduce CNI dose to achieve 50% of initial CNI target concentrations, then after 2 weeks evaluate for rejection. If no rejection, continue same regimen for an additional month, then reduce CNI further to achieve 25% of initial CNI target concentrations. Repeat biopsy 2 weeks later and if no rejection, may discontinue CNI after 2 additional weeks. Continue to maintain sirolimus trough concentrations between 10 and 15 ng/mL after CNI discontinuation (usual doses required to maintain target levels: 1 to 8 mg daily) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16364861']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16364861'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="89ffd9a5-ace6-49d9-a899-883f2d1206f7">Kidney transplantation, rejection prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Kidney transplantation, rejection prophylaxis: Note:</b> Use generally avoided in patients with hyperlipidemia (ie, serum cholesterol &gt;300 mg/dL, triglycerides &gt;400 mg/dL), serum creatinine &gt;4 mg/dL, or proteinuria &gt;1 g/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17100699']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17100699'])">Ref</a></span>). Dose and target sirolimus trough concentrations must be highly individualized based on time from transplant, assay method, and concurrent therapies. The following are examples of dosing regimens based on the available literature; refer also to institutional protocols:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Initial dosage:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Calcineurin inhibitor minimization:</i> Oral:</b> 6 mg loading dose on day 1, followed by 2 mg once daily (per manufacturer) in combination with calcineurin inhibitor (CNI) and corticosteroids; adjust dose to maintain trough concentrations between 3 and 8 ng/mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32732848']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32732848'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Calcineurin inhibitor avoidance</i>
<i>:</i> Oral: </b>12 to 15 mg loading dose between 4 and 24 hours after last CNI dose, followed by 4 to 8 mg once daily thereafter (in combination with adjunctive agents and corticosteroids); adjust dose to maintain trough concentrations between 8 and 12 ng/mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26914542','lexi-content-ref-19155978']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26914542','lexi-content-ref-19155978'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage adjustment:</b> Adjust dose at 7- to 14-day intervals (due to long half-life) to maintain 24-hour trough concentrations within desired range based on risk and concomitant therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="09a21bb1-4d08-48a5-aacd-2fb0d5dbc97f">Liver transplantation, rejection prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Liver transplantation, rejection prophylaxis (off-label use): Note</b>: Sirolimus should not be used until &gt;30 days post transplant to mitigate the risk of hepatic artery thrombosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28230639']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28230639'])">Ref</a></span>). Dose and target sirolimus trough concentrations must be highly individualized based on time from transplant, assay method, and concurrent therapies. The following are examples of dosing regimens based on the available literature; refer also to institutional protocols.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Calcineurin inhibitor minimization:</b></i>
<b>Oral: </b>2 mg once daily in combination with a calcineurin inhibitor (CNI), with or without corticosteroids; reduce the CNI dose by 50% when sirolimus is initiated. Adjust sirolimus dose to maintain target trough concentrations between 4 and 10 ng/mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31577671','lexi-content-ref-11510015','lexi-content-ref-17100699']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31577671','lexi-content-ref-11510015','lexi-content-ref-17100699'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Calcineurin inhibitor avoidance:</i> Oral:</b> 2 to 4 mg once daily in combination with mycophenolic acid derivatives, with or without corticosteroids; initiate sirolimus within 24 hours after the last dose of the CNI. Adjust dose to maintain sirolimus trough concentrations between 5 and 10 ng/mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23775875']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23775875'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e1c15325-aae4-4aea-9839-4d03245520ea">Lung transplantation, rejection prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lung transplantation, rejection prophylaxis (off-label use): </b>
<b>Note:</b> Do not initiate sirolimus until after the bronchial anastomosis has completely healed (approximately 90 days) due to potential fatal airway dehiscence with earlier initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12792493']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12792493'])">Ref</a></span>). Dose and target sirolimus trough concentrations must be highly individualized based on time from transplant, assay method, and concurrent therapies. The following is an example of a dosing regimen based on the available literature; refer also to institutional protocols.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Calcineurin inhibitor minimization:</i> Oral: </b>1 to 2 mg once daily in combination with a calcineurin inhibitor (CNI), with or without corticosteroids; reduce CNI trough target once sirolimus is initiated. Adjust sirolimus dose to maintain target trough concentrations between 6 and 10 ng/mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15797743']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15797743'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="415736d6-eb1f-4e2d-b30d-1df7379e0f74">Lymphangioleiomyomatosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lymphangioleiomyomatosis:</b> Initial: <b>Oral:</b> 2 mg once daily. Obtain first trough concentration in 10 to 21 days; adjust dose to maintain a target concentration of 5 to 15 ng/mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21410393','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21410393','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage adjustment:</b> Once the maintenance dose is adjusted, further adjustments should be made at 7- to 14-day intervals to account for the long half-life of sirolimus. In general, dose proportionality may be assumed. New sirolimus dose <b>equals</b> current dose <b>multiplied by</b> (target concentration <b>divided by</b> current concentration). Once a stable dose is achieved, trough concentrations should be assessed at least every 3 months.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f60e5d96-d49c-4d3e-9a15-ee48bcbc253e">Renal angiomyolipoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal angiomyolipoma (off-label use):</b> Initial: <b>Oral:</b> 0.5 mg/m<sup>2</sup> once daily titrated to a target trough level of 3 to 6 ng/mL (may increase to target trough level of 6 to 10 ng/mL if &lt;10% reduction in lesion diameters at 2 months) for 2 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21525172']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21525172'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991033"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment is necessary. However, adjustment of regimen (including discontinuation of therapy) should be considered when used concurrently with cyclosporine and elevated or increasing serum creatinine is noted.</p></div>
<div class="block doha drugH1Div" id="F50988262"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Loading dose: No dosage adjustment is necessary.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Maintenance dose: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mild to moderate impairment (Child-Pugh classes A and B): Reduce maintenance dose by ~33%.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Severe impairment (Child-Pugh class C): Reduce maintenance dose by ~50%.</p></div>
<div class="block doe drugH1Div" id="F221231"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F221242"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12761" href="/d/html/12761.html" rel="external">see "Sirolimus (conventional): Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Sirolimus tablets and oral solution are not bioequivalent due to differences in absorption; however, clinical equivalence has been demonstrated at the 2 mg dose. Dosage should be individualized and based on monitoring of serum trough concentrations; target range is variable and may depend upon transplantation type, length of time since transplant, renal function, infection, rejection history, drug combinations used, and side effects of individual agents.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="aa4d1573-ae88-4e22-85fd-4b83639f479a">Heart transplantation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heart transplantation:</b> Limited data available: Children and Adolescents: Oral: <b>Note:</b> Not used first-line; most data describes as alternative immunosuppression in combination with either cyclosporine or tacrolimus in patients for renal-sparing effects, following retransplantation (treatment of rejection) or to prevent or promote regression of transplant coronary artery disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21028918']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21028918'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">BSA/weight-directed dosing:</p>
<p style="text-indent:-2em;margin-left:6em;">Loading dose: 3 mg/m<sup>2</sup> on day 1 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16678029','lexi-content-ref-21028918']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16678029','lexi-content-ref-21028918'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance dose: Evaluate serum trough concentrations and adjust dose to overall target range: 4-12 ng/mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20643330']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20643330'])">Ref</a></span>). Some trials report using lower target ranges of 4-10 ng/mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21883751','lexi-content-ref-15701435','lexi-content-ref-20214748']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21883751','lexi-content-ref-15701435','lexi-content-ref-20214748'])">Ref</a></span>). In children, a specific maintenance dose has not been reported in the majority of trials. In 16 pediatric patients (age range: 2-18 years), the mean reported dose to reach target serum concentration of 5-10 ng/mL was 7 mg/m<sup>2</sup> (or 0.25 mg/kg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15701435']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15701435'])">Ref</a></span>). One trial used an initial median dose of 1 mg once daily (range: 0.3-2 mg once daily) and adjusted to achieve target concentration of 4-8 ng/mL (final dosage range 0.3-4 mg once daily) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20214748']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20214748'])">Ref</a></span>). In adolescents &lt;40 kg, an initial maintenance dose of 1 mg/m<sup>2</sup>/day in 1-2 divided doses has been suggested (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21028918']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21028918'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Alternative fixed dosing: Adolescents with weight ≥40 kg: Loading dose: 6 mg on day 1; then maintenance: 2 mg once daily; evaluate serum trough concentrations and adjust dose to overall target range: 4-12 ng/mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21028918','lexi-content-ref-20643330']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21028918','lexi-content-ref-20643330'])">Ref</a></span>); some suggest higher initial targets when sirolimus therapy initiated and then decrease to 4-8 ng/mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16678029','lexi-content-ref-21883751','lexi-content-ref-15701435']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16678029','lexi-content-ref-21883751','lexi-content-ref-15701435'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ff314d9d-9f87-4328-b04b-7c82ef5fc479">Renal transplantation, prophylaxis of organ rejection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal transplantation, prophylaxis of organ rejection (low to moderate immunologic risk):</b> Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Conversion from tacrolimus in patients with stable graft function: Children and Adolescents: Limited data available: Initial maintenance dose: 3 mg/m<sup>2</sup>/day divided every 12 hours; adjust dose to achieve target sirolimus serum trough concentration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18282210','lexi-content-ref-21338459']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18282210','lexi-content-ref-21338459'])">Ref</a></span>). In one trial, a loading dose of 5 mg/m<sup>2</sup> on day 1 was used, followed by maintenance doses of 3 mg/m<sup>2</sup>/day divided every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18282210']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18282210'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Manufacturer's recommendations: Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Weight &lt;40 kg: Loading dose: 3 mg/m<sup>2</sup> on day 1; initial maintenance dose: 1 mg/m<sup>2</sup>/day divided every 12 hours or once daily; adjust dose to achieve target sirolimus trough blood concentration</p>
<p style="text-indent:-2em;margin-left:6em;">Weight ≥40 kg: Loading dose: 6 mg on day 1; maintenance: 2 mg once daily; adjust dose to achieve target sirolimus trough blood concentration.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dosage adjustment:</i> Sirolimus dosages should be adjusted to maintain trough concentrations within desired range based on risk and concomitant therapy; maximum daily dose: 40 mg/<b>day</b>. Dosage should be adjusted at intervals of 7-14 days to account for the long half-life of sirolimus; in children receiving twice-daily dosing, serum concentrations should be checked earlier due to pharmacokinetic differences. In general, dose proportionality may be assumed. New sirolimus dose <b>equals</b> current dose <b>multiplied by</b> (target concentration/current concentration). <b>Note:</b> If large dose increase is required, consider loading dose calculated as:</p>
<p style="text-indent:-2em;margin-left:6em;">Loading dose <b>equals</b> (new maintenance dose <b>minus</b> current maintenance dose) <b>multiplied by</b> 3</p>
<p style="text-indent:-2em;margin-left:6em;">Maximum daily dose: 40 mg/day; if required dose is &gt;40 mg (due to loading dose), divide over 2 days. Serum concentrations should not be used as the sole basis for dosage adjustment (monitor clinical signs/symptoms, tissue biopsy, and laboratory parameters).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Maintenance therapy after withdrawal of cyclosporine:</i> Following 2-4 months of combined therapy, withdrawal of cyclosporine may be considered in low to moderate risk patients. Cyclosporine should be discontinued over 4-8 weeks, and a necessary increase in the dosage of sirolimus (up to fourfold) should be anticipated due to removal of metabolic inhibition by cyclosporine and to maintain adequate immunosuppressive effects.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="27da785c-c5d2-450d-81cd-f9ec398e7886">Vascular anomalies/tumors; refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vascular anomalies/tumors (eg, Kaposiform hemangioendothelioma); refractory:</b> Very limited data available: Infants ≥7 months, Children, and Adolescents ≤14 years: Oral: Oral solution: Initial: 0.8 mg/m<sup>2</sup> twice daily (approximately every 12 hours); titrate to a serum trough concentration of 10-15 ng/mL; dosing based on a pilot case series (n=6), the mean response time was 25 days (range: 8-65 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21445948']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21445948'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51160091"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary (in loading or maintenance dose); however, adjustment of regimen (including discontinuation of therapy) should be considered when used concurrently with cyclosporine and elevated or increasing serum creatinine is noted.</p></div>
<div class="block dohp drugH1Div" id="F51160092"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Loading dose: No dosage adjustment required.</p>
<p style="text-indent:-2em;margin-left:2em;">Maintenance dose:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate hepatic impairment: Reduce maintenance dose by ~33%.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe hepatic impairment: Reduce maintenance dose by ~50%.</p></div>
<div class="block adr drugH1Div" id="F221193"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Incidence of many adverse effects is dose related. Reported events exclusive to renal transplant recipients unless otherwise noted. Frequency not always defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Peripheral edema (≥20% to 58%, LAM and renal transplants), hypertension (49%), edema (18% to 20%), chest pain (LAM), deep vein thrombosis, pulmonary embolism, tachycardia</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Headache (≥20% to 34%, LAM and renal transplants), pain (29% to 33%), dizziness (LAM)</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Acne vulgaris (≥20% to 22%, LAM and renal transplants), skin rash (10% to 20%)</p>
<p style="text-indent:-2em;margin-left:2em;">Endocrine &amp; metabolic: Hypertriglyceridemia (45% to 57%), hypercholesterolemia (≥20% to 46%, LAM and renal transplants), amenorrhea, diabetes mellitus, hypermenorrhea, hypervolemia, hypokalemia, increased lactate dehydrogenase, menstrual disease, ovarian cyst</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Constipation (36% to 38%), abdominal pain (≥20% to 36%, LAM and renal transplants), diarrhea (≥20% to 35%, LAM and renal transplants), nausea (≥20% to 31%, LAM and renal transplants), stomatitis (3% to &gt;20%)</p>
<p style="text-indent:-2em;margin-left:2em;">Genitourinary: Urinary tract infection (33%)</p>
<p style="text-indent:-2em;margin-left:2em;">Hematologic &amp; oncologic: Anemia (23% to 33%), thrombocytopenia (14% to 30%), lymphoproliferative disorder (≤3%; including lymphoma), skin carcinoma (≤3%; includes basal cell carcinoma, squamous cell carcinoma, melanoma), hemolytic-uremic syndrome, leukopenia, lymphocele, thrombotic thrombocytopenic purpura</p>
<p style="text-indent:-2em;margin-left:2em;">Infection: Herpes simplex infection, herpes zoster, sepsis</p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular &amp; skeletal: Arthralgia (25% to 31%), myalgia (LAM), osteonecrosis</p>
<p style="text-indent:-2em;margin-left:2em;">Renal: Increased serum creatinine (39% to 40%), pyelonephritis</p>
<p style="text-indent:-2em;margin-left:2em;">Respiratory: Nasopharyngitis (LAM), epistaxis, pneumonia, upper respiratory tract infection (LAM)</p>
<p style="text-indent:-2em;margin-left:2em;">Miscellaneous: Wound healing impairment</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;3%, postmarketing, and/or case reports: Abnormal hepatic function tests, anaphylactoid reaction, anaphylaxis, angioedema, ascites, azoospermia, cardiac tamponade, cytomegalovirus, dehiscence (fascial), Epstein-Barr infection, exfoliative dermatitis, fluid retention, focal segmental glomerulosclerosis, gingival hyperplasia, hepatic necrosis, hepatotoxicity, hyperglycemia, hypersensitivity angiitis, hypersensitivity reaction, hypophosphatemia, incisional hernia, increased serum ALT, increased serum AST, increased susceptibility to infection (including opportunistic), interstitial pulmonary disease (dose related; includes pneumonitis, pulmonary fibrosis, and bronchiolitis obliterans organizing pneumonia with no identified infectious etiology), joint disorders, lymphedema, Merkel cell carcinoma, mycobacterium infection, nephrotic syndrome, neutropenia, pancreatitis, pancytopenia, pericardial effusion, pleural effusion, pneumonia due to <i>Pneumocystis carinii</i>, progressive multifocal leukoencephalopathy, proteinuria, pseudomembranous colitis, pulmonary alveolitis, pulmonary hemorrhage, renal disease (BK virus-associated), reversible posterior leukoencephalopathy syndrome, tuberculosis, weight loss, wound dehiscence</p></div>
<div class="block coi drugH1Div" id="F221207"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to sirolimus or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F221190"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylactic/hypersensitivity reactions: Hypersensitivity reactions, including anaphylactic/anaphylactoid reactions, angioedema, exfoliative dermatitis, and hypersensitivity vasculitis have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Angioedema: Has been reported; risk is increased in patients with elevated sirolimus levels and/or concurrent use with other drugs known to cause angioedema (eg, ACE inhibitors). Angioedema resolved following discontinuation or dose reduction in some cases.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infections: Immunosuppressive agents, including sirolimus, increase the risk of infection. Immune suppression may also increase the risk of opportunistic infections including activation of latent viral infections (including BK virus-associated nephropathy), fatal infections, and sepsis. Prophylactic treatment for <i>Pneumocystis jirovecii</i> pneumonia (PCP) should be administered for 1 year post transplant; prophylaxis for cytomegalovirus (CMV) should be taken for 3 months post transplant in patients at risk for CMV. Progressive multifocal leukoencephalopathy (PML), an opportunistic CNS infection caused by reactivation of the JC virus, has been reported in patients receiving immunosuppressive therapy, including sirolimus. Clinical findings of PML include apathy, ataxia, cognitive deficiency, confusion, and hemiparesis; promptly evaluate any patient presenting with neurological changes; consider decreasing the degree of immunosuppression with consideration to the risk of organ rejection in transplant recipients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Interstitial lung disease: Cases of interstitial lung disease (ILD) (eg, pneumonitis, bronchiolitis obliterans organizing pneumonia [BOOP], pulmonary fibrosis) have been observed (some fatal); may be associated with pulmonary hypertension (including pulmonary arterial hypertension) and risk may be increased with higher trough levels. ILD may resolve with dose reduction or discontinuation of therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperlipidemia: May increase serum lipids (cholesterol and triglycerides). Use with caution in patients with hyperlipidemia. Monitor cholesterol/lipids; if hyperlipidemia occurs, follow current guidelines for management (diet, exercise, lipid lowering agents). Antihyperlipidemic therapy may not be effective in normalizing levels.</p>
<p style="text-indent:-2em;margin-left:4em;">• Kidney effects: May increase serum creatinine and decrease GFR with long-term combination use of sirolimus and cyclosporine. Immunosuppressed patients are at an increased risk of BK viral-associated nephropathy, which may impair kidney function and cause graft loss; consider decreasing immunosuppressive burden if evidence of deteriorating kidney function. Use with caution in patients concurrently taking medications that may alter kidney function.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lymphocele/fluid accumulation: Use has been associated with an increased risk of fluid accumulation and lymphocele. Peripheral edema, lymphedema, ascites, and pleural and pericardial effusions (including significant effusions and tamponade) were reported; use with caution in patients in whom fluid accumulation may be poorly tolerated, such as in cardiovascular disease (heart failure or hypertension) and pulmonary disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Malignancy: Immunosuppressive agents, including sirolimus, may be associated with the development of lymphoma and other malignancies, including an increased risk of skin cancer; limit sun and ultraviolet light exposure; use appropriate sun protection.</p>
<p style="text-indent:-2em;margin-left:4em;">• Proteinuria: Increased urinary protein excretion has been observed when converting kidney transplant recipients from calcineurin inhibitors to sirolimus during maintenance therapy. A higher level of proteinuria prior to sirolimus conversion correlates with a higher degree of proteinuria after conversion. In some patients, proteinuria may reach nephrotic levels; nephrotic syndrome (new onset) has been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Wound dehiscence/healing: May be associated with wound dehiscence and impaired healing; use caution in the perioperative period. Patients with a body mass index (BMI) &gt;30 kg/m<sup>2</sup> are at increased risk for abnormal wound healing.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Calcineurin inhibitors: Concurrent use with a calcineurin inhibitor (cyclosporine, tacrolimus) may increase the risk of calcineurin inhibitor-induced hemolytic uremic syndrome/thrombotic thrombocytopenic purpura/thrombotic microangiopathy (HUS/TTP/TMA).</p>
<p style="text-indent:-2em;margin-left:4em;">• Cyclosporine: Safety and efficacy of combination therapy with cyclosporine in high immunologic risk patients have not been studied beyond 12 months of treatment. Monitor kidney function closely when combined with cyclosporine; consider dosage adjustment or discontinue in patients with increasing serum creatinine.</p>
<p style="text-indent:-2em;margin-left:4em;">• Vaccines: Immunosuppressants may affect response to vaccination. Therefore, during treatment with sirolimus, vaccination may be less effective. The use of live vaccines should be avoided.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Kidney transplant: In kidney transplant recipients, de novo use without cyclosporine has been associated with higher rates of acute rejection. Sirolimus may delay recovery of kidney function in patients with delayed allograft function.</p>
<p style="text-indent:-2em;margin-left:4em;">• Liver transplants: Sirolimus is not recommended for use early post transplant; studies indicate an association with an increased risk of hepatic artery thrombosis (HAT), graft failure, and increased mortality (with evidence of infection) in these patients when sirolimus is used in combination with cyclosporine and/or tacrolimus. Most cases of HAT occurred within 30 days of transplant.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lung transplants: Sirolimus is not recommended for use early post lung transplantation. Bronchial anastomotic dehiscence cases have been reported in lung transplant recipients when sirolimus was used as part of an immunosuppressive regimen; most of these reactions were fatal.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Product interchangeability: Sirolimus tablets and oral solution are not bioequivalent, due to differences in absorption. Clinical equivalence was seen using 2 mg tablet and 2 mg solution. It is not known if higher doses are also clinically equivalent. Monitor sirolimus levels if changes in dosage forms are made.</p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Experienced physician: Should only be used by physicians experienced in immunosuppressive therapy and management of transplant recipients. Adequate laboratory and supportive medical resources must be readily available.</p>
<p style="text-indent:-2em;margin-left:4em;">• Laboratory monitoring: Sirolimus concentrations are dependent on the assay method (eg, chromatographic and immunoassay) used; assay methods are not interchangeable. Variations in methods to determine sirolimus whole blood concentrations, as well as interlaboratory variations, may result in improper dosage adjustments, which may lead to subtherapeutic or toxic levels. Determine the assay method used to assure consistency (or accommodations if changes occur), and for monitoring purposes, be aware of alterations to assay method or reference range and that values from different assays may not be interchangeable.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878632"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Animal studies have indicated that sirolimus may inhibit skeletal and muscle growth. There has been at least one human case report of growth failure in a child (Hymes, 2011).  </p></div>
<div class="block foc drugH1Div" id="F221201"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rapamune: 1 mg/mL (60 mL) [contains alcohol, usp, polysorbate 80, propylene glycol, soybeans (glycine soja)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg/mL (60 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rapamune: 0.5 mg, 1 mg, 2 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5 mg, 1 mg, 2 mg</p></div>
<div class="block geq drugH1Div" id="F221186"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F221209"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Rapamune Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/mL (per mL): $39.28</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Sirolimus Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/mL (per mL): $31.58 - $35.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Rapamune Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg (per each): $20.63</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $41.25</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $82.50</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Sirolimus Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg (per each): $8.47 - $8.65</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $16.95 - $17.05</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $31.50 - $33.90</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868239"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rapamune: 1 mg/mL (60 mL) [contains alcohol, usp, polysorbate 80, propylene glycol, soybean oil]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rapamune: 1 mg</p></div>
<div class="block adm drugH1Div" id="F221204"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer consistently (either with or without food). <i>Kidney </i>
<i>transplant:</i> Sirolimus should be taken 4 hours after oral cyclosporine (Neoral or Gengraf).</p>
<p style="text-indent:-2em;margin-left:4em;">Solution: Mix (by stirring vigorously) with at least 60 mL of water or orange juice. No other liquids should be used for dilution. Patient should drink diluted solution immediately. The cup should then be refilled with an additional 120 mL of water or orange juice, stirred vigorously, and the patient should drink the contents at once.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet: Do not crush, split, or chew.</p></div>
<div class="block admp drugH1Div" id="F52613856"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May be taken with or without food, but take medication consistently with respect to meals to minimize absorption variability. Initial dose should be administered as soon as possible after transplant. Sirolimus should be taken 4 hours after oral cyclosporine (Neoral or Gengraf).</p>
<p style="text-indent:-2em;margin-left:2em;">Oral solution: Use amber oral syringe to withdraw solution from the bottle. Empty dose from syringe into a glass or plastic cup and mix with at least 2 ounces of water or orange juice. No other liquids should be used for dilution. Patient should stir vigorously and drink the diluted sirolimus solution immediately. Then refill cup with an additional 4 ounces of water or orange juice; stir contents vigorously and have patient drink solution at once.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral tablets: Do not crush, split, or chew.</p></div>
<div class="block hazard drugH1Div" id="F49133426"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 2]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block meg drugH1Div" id="F11310396"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2020%2F021083s067%2C021110s085lbl.pdf%23page%3D43&amp;token=yQD0FQI4uFBv9GVwQ9kDoPIJe%2Blyap0ym6GYAWRAhqKJbtYQKkAtBEtah8L3dAzx57rwuPaCJ9jQ90OJ6JPjISQSz0npidt7e739Z%2BRl1aQD1K3v98sGpjr55fKtEgQP&amp;TOPIC_ID=10329" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021083s067,021110s085lbl.pdf#page=43</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F221203"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Kidney transplantation (rejection prophylaxis):</b> Prophylaxis of organ rejection in patients receiving kidney transplants (in low-to-moderate immunologic risk patients in combination with cyclosporine and corticosteroids with cyclosporine withdrawn 2 to 4 months after transplant, and in high immunologic risk patients in combination with cyclosporine and corticosteroids for the first year after transplant). Therapeutic drug monitoring is recommended for all patients receiving sirolimus. High immunologic risk kidney transplant recipients are defined (per the manufacturer's labeling) as Black transplant recipients and/or repeat kidney transplant recipients who lost a previous allograft based on an immunologic process and/or patients with high PRA (panel-reactive antibodies; peak PRA level &gt;80%).</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use (kidney transplantation): Cyclosporine withdrawal has not been studied in patients with Banff grade 3 acute rejection or vascular rejection prior to cyclosporine withdrawal, patients who are dialysis-dependent, patients with serum creatinine &gt;4.5 mg/dL, Black patients, patients with multiorgan transplants or secondary transplants, or those with high levels of PRA. In patients at high immunologic risk, the safety and efficacy of sirolimus used in combination with cyclosporine and corticosteroids have not been studied beyond 1 year; therefore, after the first 12 months following transplantation, consider any adjustments to the immunosuppressive regimen on the basis of the clinical status of the patient. The safety and efficacy of sirolimus have not been established in patients younger than 13 years or in pediatric kidney transplant recipients younger than 18 years who are considered at high immunologic risk. The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines for the care of kidney transplant recipients recommend not initiating sirolimus until graft function has been established and surgical wounds have healed (KDIGO 2009). Avoid the use of sirolimus in combination with calcineurin inhibitors, particularly in the early posttransplant period due to an increased risk of nephrotoxicity (KDIGO 2009; Webster 2006).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Lymphangioleiomyomatosis:</b> Treatment of lymphangioleiomyomatosis. Therapeutic drug monitoring is recommended for all patients receiving sirolimus.</p></div>
<div class="block off-label drugH1Div" id="F25471667"><span class="drugH1">Use: Off-Label: Adult</span><p>Chordoma, advanced; Graft-versus-host disease, prevention; Graft-versus-host disease, acute, treatment; Graft-versus-host disease, chronic, treatment; Heart transplant (prophylaxis of organ rejection and allograft vasculopathy); Liver transplantation (rejection prophylaxis); Lung transplantation (rejection prophylaxis); Renal angiomyolipoma</p></div>
<div class="block mst drugH1Div" id="F4288698"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Rapamune may be confused with Rapaflo.</p>
<p style="text-indent:-2em;margin-left:4em;">Sirolimus (conventional) may be confused with everolimus, pimecrolimus, silodosin, sirolimus (protein bound), sirolimus (topical), tacrolimus, temsirolimus, temozolomide, tesamorelin.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F221246"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major), P-glycoprotein/ABCB1 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F221195"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Adalimumab: May decrease the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aldesleukin: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Androgens: Hypertension-Associated Agents may enhance the hypertensive effect of Androgens. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin-Converting Enzyme Inhibitors: Sirolimus Products may enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. Specifically, the risk for angioedema may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antihepaciviral Combination Products: May increase the serum concentration of Sirolimus (Conventional).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asciminib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bimekizumab: May decrease the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabidiol: May increase the serum concentration of Sirolimus (Conventional). Management: A dose reduction of sirolimus should be considered when combined with cannabidiol. Monitor for increased sirolimus concentrations/toxicity if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clotrimazole (Oral): May increase the serum concentration of Sirolimus (Conventional).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clotrimazole (Topical): May increase the serum concentration of Sirolimus (Conventional).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing therapeutic immunosuppressants several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Sirolimus (Conventional) may enhance the adverse/toxic effect of CycloSPORINE (Systemic). An increased risk of calcineurin inhibitor-induced hemolytic uremic syndrome/thrombotic thrombocytopenic purpura/thrombotic microangiopathy (HUS/TTP/TMA) has been described. CycloSPORINE (Systemic) may increase the serum concentration of Sirolimus (Conventional). This is of specific concern with cyclosporine [MODIFIED].  Management: Administer oral doses of sirolimus 4 hours after doses of cyclosporine.  Monitor for toxic effects of sirolimus if used with cyclosporine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Sirolimus (Conventional).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Sirolimus (Conventional). Management: Avoid concomitant use of strong CYP3A4 inducers and sirolimus if possible. If combined, monitor for reduced serum sirolimus concentrations. Sirolimus dose increases will likely be necessary to prevent subtherapeutic sirolimus levels.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Weak): May decrease the serum concentration of Sirolimus (Conventional).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Sirolimus (Conventional). Management: Monitor for increased serum concentrations of sirolimus if combined with a moderate CYP3A4 inhibitor. Lower initial sirolimus doses or sirolimus dose reductions will likely be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Sirolimus (Conventional). Management: Avoid concurrent use of sirolimus with strong CYP3A4 inhibitors when possible and alternative agents with lesser interaction potential with sirolimus should be considered. Concomitant use of sirolimus and voriconazole or posaconazole is contraindicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Weak): May increase the serum concentration of Sirolimus (Conventional).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Denosumab.  Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elacestrant: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elranatamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Epcoritamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: May decrease the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: May increase the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erythromycin (Systemic): May increase the serum concentration of Sirolimus (Conventional). Sirolimus (Conventional) may increase the serum concentration of Erythromycin (Systemic). Management: Monitor for increased serum concentrations of sirolimus if combined with erythromycin. Lower initial sirolimus doses or sirolimus dose reductions will likely be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluconazole: May increase the serum concentration of Sirolimus (Conventional). Management: Monitor for increased serum concentrations of sirolimus if combined with fluconazole. Lower initial sirolimus doses or sirolimus dose reductions will likely be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Futibatinib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Agents (Prokinetic): May increase the serum concentration of Sirolimus (Conventional).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gilteritinib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glofitamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grapefruit Juice: May increase the serum concentration of Sirolimus (Conventional).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate 2 to 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Interleukin-6 (IL-6) Inhibiting Therapies: May decrease the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Interleukin-6 (IL-6) Inhibiting Therapies: May decrease the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivosidenib: May decrease the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inducers). Management: Consider alternatives to this combination when possible. If combined, monitor for decreased effectiveness of these CYP3A4 substrates if combined with ivosidenib.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lasmiditan: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maribavir: May increase the serum concentration of Sirolimus Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: May decrease the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Micafungin: May increase the serum concentration of Sirolimus Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Milk Thistle: May increase the serum concentration of Sirolimus Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mitapivat: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mosunetuzumab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May increase the serum concentration of Sirolimus (Conventional). Management: Consider avoiding this combination, if possible, through use of alternative anti-COVID-19 therapy. If combined, hold sirolimus during nirmatrelvir/ritonavir treatment and for at least 2 to 3 days after completion. Monitor sirolimus levels closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirogacestat: May increase the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olutasidenib: May decrease the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inducers). Management: Avoid use of olutasidenib with sensitive or narrow therapeutic index CYP3A4 substrates when possible. If concurrent use with olutasidenib is unavoidable, monitor closely for evidence of decreased concentrations of the CYP3A4 substrates.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: May increase the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of Sirolimus (Conventional). Management: Avoid concurrent use of sirolimus with P-glycoprotein (P-gp) inducers when possible and alternative agents with lesser interaction potential with sirolimus should be considered. Monitor for decreased sirolimus concentrations if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of Sirolimus (Conventional). Management: Avoid concurrent use of sirolimus with P-glycoprotein (P-gp) inhibitors when possible and alternative agents with lesser interaction potential with sirolimus should be considered. Monitor for increased sirolimus concentrations/toxicity if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Pimecrolimus. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Posaconazole: May increase the serum concentration of Sirolimus (Conventional).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifabutin: May decrease the serum concentration of Sirolimus (Conventional).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: May enhance the hypertensive effect of Hypertension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sotagliflozin: May decrease the serum concentration of Sirolimus (Conventional). Sotagliflozin may increase the serum concentration of Sirolimus (Conventional). Management: Avoid concurrent use of sirolimus with sotagliflozin when possible. If combined, monitor for increases or decreases in sirolimus concentrations and increased sirolimus toxicities. Sirolimus dose adjustments may be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Spironolactone: May increase the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): May enhance the adverse/toxic effect of Sirolimus Products. Sirolimus Products may enhance the adverse/toxic effect of Tacrolimus (Systemic). Sirolimus Products may decrease the serum concentration of Tacrolimus (Systemic).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talquetamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taurursodiol: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taurursodiol: May decrease the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teclistamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tofacitinib.  Management: Coadministration of tofacitinib with potent immunosuppressants is not recommended. Use with non-biologic disease-modifying antirheumatic drugs (DMARDs) was permitted in psoriatic arthritis clinical trials.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Treosulfan: May increase the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trofinetide: May increase the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ustekinumab: May decrease the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 2 to 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voriconazole: May increase the serum concentration of Sirolimus (Conventional).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F221222"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;margin-left:0em;text-align:justify;display:inline">Grapefruit juice may decrease clearance of sirolimus. Ingestion with high-fat meals decreases peak concentrations but increases AUC by 23% to 35%. Management: Avoid grapefruit juice. Take consistently (either with or without food) to minimize variability.</p></div>
<div class="block rep_considerations drugH1Div" id="F53560181"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Patients who could become pregnant should use highly effective contraception prior to initiation of sirolimus, during treatment, and for 12 weeks after sirolimus is discontinued.</p>
<p style="text-indent:0em;margin-top:2em;">Sirolimus may impair fertility. Ovarian cysts, amenorrhea, menorrhagia, azoospermia, or oligospermia have been observed following use of oral sirolimus. Sperm banking prior to sirolimus treatment may be considered (KDIGO 2009).</p>
<p style="text-indent:0em;margin-top:2em;">Agents other than sirolimus may be preferred for patients who have had a kidney transplant and are planning to become pregnant (Agarwal 2021; Cabiddu 2018; EBPG 2002; KDIGO 2009; Longhitano 2021; López 2014).</p>
<p style="text-indent:0em;margin-top:2em;">Sirolimus has been evaluated for the treatment of recurrent implantation failure in patients undergoing in vitro fertilization (Ahmadi 2019; Wang 2021).</p></div>
<div class="block pri drugH1Div" id="F221210"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Sirolimus crosses the placenta (Barnes 2018; Park 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Based on the mechanism of action and data from animal reproduction studies, in utero exposure to sirolimus may cause fetal harm.</p>
<p style="text-indent:0em;margin-top:2em;">Outcome data following maternal use of sirolimus in pregnant patients who have had organ transplants is limited (Boulay 2021; Framarino dei Malatesta 2011; Sifontis 2006). Although an increased risk of congenital anomalies has not been observed, due to adverse events observed in animal reproduction studies, agents other than sirolimus may be preferred for use in pregnant patients who have had a kidney transplant (Agarwal 2021; Cabiddu 2018; EBPG 2002; KDIGO 2009; Longhitano 2021; López 2014; Ponticelli 2021).</p>
<p style="text-indent:0em;margin-top:2em;">The use of sirolimus for the treatment of lymphangioleiomyomatosis during pregnancy has been reported (Faehling 2015; Shen 2021); however, available data are insufficient to make recommendations (Gupta 2018; McCormack 2016).</p>
<p style="text-indent:0em;margin-top:2em;">Case reports describe maternal administration of sirolimus for the in-utero treatment of fetal cardiac rhabdomyomas that were possibly associated with tuberous sclerosis complex (Barnes 2018; Dagge 2021; Ebrahimi-Fakhari 2021; Park 2019; Pluym 2020; Vachon-Marceau 2019).</p>
<p style="text-indent:0em;margin-top:2em;">The Transplant Pregnancy Registry International (TPR) is a registry that follows pregnancies that occur in maternal transplant recipients or those fathered by male transplant recipients. The TPR encourages reporting of pregnancies following solid organ transplant by contacting them at 1-877-955-6877 or https://www.transplantpregnancyregistry.org.</p></div>
<div class="block brc drugH1Div" id="F4288699"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if sirolimus is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during sirolimus therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of sirolimus treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F221199"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Baseline fasting lipid panel; urine protein prior to initiation; also consider baseline pulmonary function testing in patients with impaired pulmonary function who are at high risk for pulmonary toxicity. Monitor organ-specific rejection parameters (eg, serum creatinine for kidney transplant recipients) and CBC during treatment. Monitor sirolimus levels in all patients (especially in pediatric patients, patients ≥13 years of age weighing &lt;40 kg, patients with hepatic impairment, or on concurrent potent inhibitors or inducers of CYP3A4 or P-gp, and/or if cyclosporine dosing is markedly reduced or discontinued), and when changing dosage forms of sirolimus. Also monitor serum cholesterol and triglycerides, blood pressure, serum creatinine, and urinary protein. Serum drug concentrations should be determined 3 to 4 days after loading doses and 7 to 14 days after dosage adjustments for kidney transplant recipients; however, these concentrations should not be used as the sole basis for dosage adjustment, especially during withdrawal of cyclosporine (monitor clinical signs/symptoms, tissue biopsy, and laboratory parameters). Monitor serum trough concentration 10 to 20 days after initiating therapy for lymphangioleiomyomatosis and 7 to 14 days after dosage adjustments. Once a stable dose is achieved, trough concentrations should be assessed at least every 3 months. <b>Note:</b> Concentrations and ranges are dependent on and will vary with assay methodology (chromatographic or immunoassay); assay methods are not interchangeable.</p>
<p style="text-indent:-2em;margin-left:2em;">Oncology uses: The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow up. Monitor adherence.</p></div>
<div class="block rer drugH1Div" id="F221202"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Sirolimus concentrations are dependent on the assay method (eg, chromatographic and immunoassay) used; assay methods are not interchangeable. Determine the assay method used to assure consistency (or accommodations if changes occur) and for monitoring purposes, be aware of alterations to assay method or reference range. Refer to institutional protocols for target sirolimus trough concentration goals.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Serum trough concentrations for advanced chordoma (off-label use):</b> 15 to 20 ng/mL (Stacchiotti 2009).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Serum trough concentrations for graft-versus-host disease prophylaxis in allogeneic stem cell transplant (off-label use):</b> 3 to 12 ng/mL (Armand 2008; Cutler 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Serum trough concentrations for lymphangioleiomyomatosis</b>: 5 to 15 ng/mL.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Serum trough concentrations for renal angiomyolipoma (off-label use):</b> 3 to 6 ng/mL; may increase to 6 to 10 ng/mL if &lt;10% reduction in lesion diameters at 2 months (Davies 2011).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Serum trough concentrations for solid organ transplant (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> The following indication-specific target trough concentrations are based on the available literature; however, levels must be highly individualized based on time from transplant, assay method, concurrent therapies, and other patient-specific factors (eg, rejection history).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Heart transplantation (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:6em;">With calcineurin inhibitor (eg, cyclosporine): 4 to 15 ng/mL (Mancini 2003) <b>or </b>4 to 12 ng/mL (ISHLT [Velleca 2022]).</p>
<p style="text-indent:-2em;margin-left:6em;">Following conversion from calcineurin inhibitor to sirolimus (calcineurin inhibitor withdrawal):</p>
<p style="text-indent:-2em;margin-left:8em;">Immediate calcineurin inhibitor dose reduction approach (maintained until completion of conversion [~2 weeks]): 8 to 14 ng/mL (Topilsky 2012).</p>
<p style="text-indent:-2em;margin-left:8em;">Delayed calcineurin inhibitor dose reduction approach: 10 to 15 ng/mL (Kushwaha 2005).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Kidney transplantation:</b></p>
<p style="text-indent:-2em;margin-left:6em;">With calcineurin inhibitor: 3 to 8 ng/mL (Cucchiari 2020).</p>
<p style="text-indent:-2em;margin-left:6em;">Without calcineurin inhibitor: 8 to 12 ng/mL (Fleming 2016).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Liver transplantation (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:6em;">With calcineurin inhibitor: 4 to 10 ng/mL (Buchholz 2020).</p>
<p style="text-indent:-2em;margin-left:6em;">Without calcineurin inhibitor: 5 to 10 ng/mL (Teperman 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Lung transplantation (off-label use):</b> With calcineurin inhibitor: 6 to 10 ng/mL (Villanueva 2005).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Note: </b>The following trough concentrations for kidney transplantation are based on the manufacturer's labeling, but may not reflect current practice:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Serum trough concentration goals for kidney transplantation</b> (based on HPLC methods):</p>
<p style="text-indent:-2em;margin-left:6em;">Concomitant cyclosporine: 4 to 12 ng/mL.</p>
<p style="text-indent:-2em;margin-left:6em;">Low to moderate immunologic risk (after cyclosporine withdrawal): 8 to 12 ng/mL.</p>
<p style="text-indent:-2em;margin-left:6em;">High immunologic risk (with cyclosporine): 10 to 15 ng/mL.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Trough concentrations vary based on clinical context and use of additional immunosuppressants. The following represents typical ranges.</p>
<p style="text-indent:-2em;margin-left:6em;">When combined with tacrolimus and mycophenolate mofetil without steroids: 6 to 8 ng/mL.</p>
<p style="text-indent:-2em;margin-left:6em;">As a substitute for tacrolimus (starting 4 to 8 weeks post transplant), in combination with mycophenolate mofetil and steroids: 8 to 12 ng/mL.</p>
<p style="text-indent:-2em;margin-left:6em;">Following conversion from tacrolimus to sirolimus &gt;6 months post transplant due to chronic allograft nephropathy: 4 to 6 ng/mL.</p></div>
<div class="block pha drugH1Div" id="F221189"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Sirolimus inhibits T-lymphocyte activation and proliferation in response to antigenic and cytokine stimulation and inhibits antibody production. Its mechanism differs from other immunosuppressants. Sirolimus binds to FKBP-12, an intracellular protein, to form an immunosuppressive complex which inhibits the regulatory kinase, mTOR (mechanistic target of rapamycin). This inhibition suppresses cytokine mediated T-cell proliferation, halting progression from the G1 to the S phase of the cell cycle. It inhibits acute rejection of allografts and prolongs graft survival.</p>
<p style="text-indent:0em;margin-top:2em;">In lymphangioleiomyomatosis, the mTOR signaling pathway is activated through the loss of the tuberous sclerosis complex (TSC) gene function (resulting in cellular proliferation and release of lymphangiogenic growth factors). By inhibiting the mTOR pathway, sirolimus prevents the proliferation of lymphangioleiomyomatosis cells.</p></div>
<div class="block phk drugH1Div" id="F221206"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Rapid</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: 12 L/kg (range: 4 to 20 L/kg)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: ~92%, primarily to albumin</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Extensive; in intestinal wall via P-glycoprotein and  hepatic via CYP3A4 to 7 major metabolites</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: Oral solution: 14%; Oral tablet: 27% higher relative to the oral solution; oral solution and tablets are not bioequivalent however, clinical equivalence shown at 2 mg dose</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Children: 13.7 ± 6.2 hours</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adults: Mean: 62 hours (range: 46 to 78 hours); extended in hepatic impairment (Child-Pugh class A or B) to 113 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak: Oral solution: 1 to 3 hours; Tablet: 1 to 6 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Feces (91% due to P-glycoprotein-mediated efflux into gut lumen); urine (2%)</p></div>
<div class="block phksp drugH1Div" id="F51159900"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Minimal (2.2%) renal excretion of the drug and its metabolites.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Patients with mild, moderate, and severe hepatic impairment had 43%, 94%, and 189% higher mean values for sirolimus AUC, respectively, with no statistically significant differences in mean C<sub>max</sub>. As the severity of hepatic impairment increased, there were steady increases in mean sirolimus half-life and decreases in the mean sirolimus clearance normalized for body weight.</p>
<p style="text-indent:-2em;margin-left:2em;">Sex: Clearance is 12% lower and the half-life is prolonged in men compared with women (~72 hours versus ~61 hours, respectively).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F221212"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Rapamune</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Rapamune</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Rapamune</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Rapamune</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Rapamune</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Rapamune</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Rapamune</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Rapamune</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Rapamune | Rui pa ming</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Rapamune</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Rapamune</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Rapamune</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Rapamune</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Rapamune</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Rapamune</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Rapamune</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Rapamune</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Rapamune</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Rapamune</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Rapamune</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Rapamune</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Rapamune</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Emtor | Siromus</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Rapamune sirolimus</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Rapamune</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Rapamune</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Cyclentra | P hysplan | Padawat | Rapamune | Renacept</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Rapamune</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Rapamune</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Rapamune</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Rapamune</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Rapamune</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Siroall | Sirograf</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Rapamune</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Rapamune</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Rapamune</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Rapamune</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Rapamune</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Rapamune</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Rapamune</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Rapamune</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Rapamune</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Rapamune</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Rapamune</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Rapamune</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Rapamune</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Rapamune</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Rapamune</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USPNF.1">
<a name="USPNF.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34693263">
<a name="34693263"></a>Agarwal KA, Pavlakis M. Sexuality, contraception, and pregnancy in kidney transplantation. <i>Kidney Med</i>. 2021;3(5):837-847. doi:10.1016/j.xkme.2021.05.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/34693263/pubmed" id="34693263" target="_blank">34693263</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31299610">
<a name="31299610"></a>Ahmadi M, Abdolmohamadi-Vahid S, Ghaebi M, et al. Sirolimus as a new drug to treat RIF patients with elevated Th17/Treg ratio: a double-blind, phase II randomized clinical trial. <i>Int Immunopharmacol</i>. 2019;74:105730. doi:10.1016/j.intimp.2019.105730<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/31299610/pubmed" id="31299610" target="_blank">31299610</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12730113">
<a name="12730113"></a>Antin J, Kim H, Cutler C, et al, "Sirolimus, Tacrolimus, and Low-Dose Methotrexate for Graft-Versus-Host Disease Prophylaxis in Mismatched Related Donor or Unrelated Donor Transplantation," <i>Blood</i>, 2003, 102(5):1601-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/12730113/pubmed" id="12730113" target="_blank">12730113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19001324">
<a name="19001324"></a>Armand P, Gannamaneni S, Kim HT, et al, “Improved Survival in Lymphoma Patients Receiving Sirolimus for Graft-Versus-Host Disease Prophylaxis After Allogeneic Hematopoietic Stem-Cell Transplantation With Reduced-Intensity Conditioning,” <i>J Clin Oncol</i>, 2008, 26(35):5767-74.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/19001324/pubmed" id="19001324" target="_blank">19001324</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16678029">
<a name="16678029"></a>Balfour IC, Srun SW, Wood EG, et al, "Early Renal Benefit of Rapamycin Combined With Reduced Calcineurin Inhibitor Dose in Pediatric Heart Transplantation Patients," <i>J Heart Lung Transplant</i>, 2006, 25(5):518-22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/16678029/pubmed" id="16678029" target="_blank">16678029</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29742370">
<a name="29742370"></a>Barnes BT, Procaccini D, Crino J, et al. Maternal sirolimus therapy for fetal cardiac rhabdomyomas. <i>N Engl J Med</i>. 2018;378(19):1844-1845. doi:10.1056/NEJMc1800352<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/29742370/pubmed" id="29742370" target="_blank">29742370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11773890">
<a name="11773890"></a>Benito AI, Furlong T, Martin PJ, et al, “Sirolimus (Rapamycin) for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease,” <i>Transplantation</i>, 2001, 72(12):1924-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/11773890/pubmed" id="11773890" target="_blank">11773890</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18184959">
<a name="18184959"></a>Bissler JJ, McCormack FX, Young LR, et al, “Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis,” <i>N Engl J Med</i>, 2008, 358(2):140-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/18184959/pubmed" id="18184959" target="_blank">18184959</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34345409">
<a name="34345409"></a>Boulay H, Mazaud-Guittot S, Supervielle J, et al. Maternal, foetal and child consequences of immunosuppressive drugs during pregnancy in women with organ transplant: a review. <i>Clin Kidney J</i>. 2021;14(8):1871-1878. doi:10.1093/ckj/sfab049<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/34345409/pubmed" id="34345409" target="_blank">34345409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31577671">
<a name="31577671"></a>Buchholz BM, Ferguson JW, Schnitzbauer AA, et al; International SiLVER study group. Randomized sirolimus-based early calcineurin inhibitor reduction in liver transplantation: impact on renal function. <i>Transplantation</i>. 2020;104(5):1003-1018. doi:10.1097/TP.0000000000002980<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/31577671/pubmed" id="31577671" target="_blank">31577671</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29949013">
<a name="29949013"></a>Cabiddu G, Spotti D, Gernone G, et al; Kidney and Pregnancy Study Group of the Italian Society of Nephrology. A best-practice position statement on pregnancy after kidney transplantation: focusing on the unsolved questions. The Kidney and Pregnancy Study Group of the Italian Society of Nephrology. <i>J Nephrol</i>. 2018;31(5):665-681. doi:10.1007/s40620-018-0499-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/29949013/pubmed" id="29949013" target="_blank">29949013</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12581765">
<a name="12581765"></a>Cahill BC, Somerville KT, Crompton JA, et al. Early experience with sirolimus in lung transplant recipients with chronic allograft rejection. <i>J Heart Lung</i>
<i>Transplant</i>. 2003;22(2):169-176. doi:10.1016/s1053-2498(02)00550-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/12581765/pubmed" id="12581765" target="_blank">12581765</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29485508">
<a name="29485508"></a>Charlton M, Levitsky J, Aqel B, et al. International Liver Transplantation Society consensus statement on immunosuppression in liver transplant recipients. <i>Transplantation</i>. 2018;102(5):727-743. doi:10.1097/TP.0000000000002147<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/29485508/pubmed" id="29485508" target="_blank">29485508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21883751">
<a name="21883751"></a>Chinnock TJ, Shankel T, Deming D, et.al. Calcineurin inhibitor minimization using sirolimus leads to improved renal function in pediatric heart transplant recipients. <i>Pediatric Transplantation</i>. 2011;15:746-749.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/21883751/pubmed" id="21883751" target="_blank">21883751</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20643330">
<a name="20643330"></a>Costanzo MR, Dipchand A, Starling R, et al. "The International Society of Heart and Lung Transplantation Guidelines for the Care of Heart Transplant Recipients," <i>J Heart Lung Transplant, </i>2010, 29(8):914-56.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/20643330/pubmed" id="20643330" target="_blank">20643330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16042691">
<a name="16042691"></a>Couriel DR, Saliba R, Escalon MP, et al, “Sirolimus in Combination With Tacrolimus and Corticosteroids for the Treatment of Resistant Chronic Graft-Versus-Host Disease,” <i>Br J Haematol</i>, 2005, 130(3):409-17.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/16042691/pubmed" id="16042691" target="_blank">16042691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32732848">
<a name="32732848"></a>Cucchiari D, Molina-Andujar A, Montagud-Marrahi E, et al. Use of de novo mTOR inhibitors in hypersensitized kidney transplant recipients: experience from clinical practice. <i>Transplantation</i>. 2020;104(8):1686-1694. doi:10.1097/TP.0000000000003021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/32732848/pubmed" id="32732848" target="_blank">32732848</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15111932">
<a name="15111932"></a>Cutler C, Kim H, Hochberg E, et al, "Sirolimus and Tacrolimus Without Methotrexate as Graft-Versus-Host Disease Prophylaxis After Matched Related Donor Peripheral Blood Stem Cell Transplantation,” <i>Biol Blood Marrow Transplant</i>, 2004, 10(5):328-36.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/15111932/pubmed" id="15111932" target="_blank">15111932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17138818">
<a name="17138818"></a>Cutler C, Li S, Ho VT, et al, “Extended Follow-Up of Methotrexate-Free Immunosuppression Using Sirolimus and Tacrolimus in Related and Unrelated Donor Peripheral Blood Stem Cell Transplantation,” <i>Blood</i>, 2007, 109(7):3108-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/17138818/pubmed" id="17138818" target="_blank">17138818</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34281475">
<a name="34281475"></a>Dagge A, Silva LA, Jorge S, Nogueira E, Rebelo M, Pinto L. Fetal tuberous sclerosis: sirolimus for the treatment of fetal rhabdomyoma. <i>Fetal Pediatr Pathol</i>. 2021:1-7. doi:10.1080/15513815.2021.1948646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/34281475/pubmed" id="34281475" target="_blank">34281475</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21525172">
<a name="21525172"></a>Davies DM, de Vries PJ, Johnson SR, et al, “Sirolimus Therapy for Angiomyolipoma in Tuberous Sclerosis and Sporadic Lymphangioleiomyomatosis: A Phase 2 Trial,” <i>Clin Cancer Res</i>, 2011, 17(12):4071-81.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/21525172/pubmed" id="21525172" target="_blank">21525172</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21028918">
<a name="21028918"></a>Denfield SW. Strategies to prevent cellular rejection in pediatric heart transplant recipients. <i>Pediatric Drugs</i>. 2010;12(6):391-403.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/21028918/pubmed" id="21028918" target="_blank">21028918</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15476488">
<a name="15476488"></a>Diekmann F, Budde K, Oppenheimer F, Fritsche L, Neumayer HH, Campistol JM. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. <i>Am J Transplant</i>. 2004;4(11):1869-1875. doi:10.1111/j.1600-6143.2004.00590.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/15476488/pubmed" id="15476488" target="_blank">15476488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34624607">
<a name="34624607"></a>Ebrahimi-Fakhari D, Stires G, Hahn E, Krueger D, Franz DN. Prenatal sirolimus treatment for rhabdomyomas in tuberous sclerosis. <i>Pediatr Neurol</i>. 2021;125:26-31. doi:10.1016/j.pediatrneurol.2021.09.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/34624607/pubmed" id="34624607" target="_blank">34624607</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12091650">
<a name="12091650"></a>EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: long-term management of the transplant recipient. IV.10. Pregnancy in renal transplant recipients. <i>Nephrol Dial Transplant</i>. 2002;17(suppl 4):50-55.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/12091650/pubmed" id="12091650" target="_blank">12091650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11583941">
<a name="11583941"></a>Ettinger RB and Grimm EM, “Safety and Efficacy of TOR Inhibitors in Pediatric Renal Transplant Recipients,” <i>Am J Kidney Dis</i>, 2001, 38(4 Suppl 2):22-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/11583941/pubmed" id="11583941" target="_blank">11583941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22830463">
<a name="22830463"></a>Euvrard S, Morelon E, Rostaing L, et al, “Sirolimus and Secondary Skin-Cancer Prevention in Kidney Transplantation,” <i>N Engl J Med</i>, 2012, 367(4):329-39.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/22830463/pubmed" id="22830463" target="_blank">22830463</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26422572">
<a name="26422572"></a>Faehling M, Wienhausen-Wilke V, Fallscheer S, Trinajstic-Schulz B, Weber J, Leschke M. Long-term stable lung function and second uncomplicated pregnancy on sirolimus in lymphangioleiomyomatosis (LAM). <i>Sarcoidosis Vasc Diffuse Lung Dis</i>. 2015;32(3):259-264.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/26422572/pubmed" id="26422572" target="_blank">26422572</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26914542">
<a name="26914542"></a>Fleming JN, Taber DJ, Pilch NA, et al. A randomized, prospective comparison of transition to sirolimus-based CNI-minimization or withdrawal in African American kidney transplant recipients. <i>Clin Transplant</i>. 2016;30(5):528-533. doi:10.1111/ctr.12718<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/26914542/pubmed" id="26914542" target="_blank">26914542</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21508801">
<a name="21508801"></a>Framarino dei Malatesta M, Corona LE, De Luca L, et al. Successful pregnancy in a living-related kidney transplant recipient who received sirolimus throughout the whole gestation. <i>Transplantation</i>. 2011;91(9):e69-e71. doi: 10.1097/TP.0b013e3182154267.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/21508801/pubmed" id="21508801" target="_blank">21508801</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26555945">
<a name="26555945"></a>Geissler EK, Schnitzbauer AA, Zülke C, et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial. <i>Transplantation</i>. 2016;100(1):116-125. doi:10.1097/TP.0000000000000965<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/26555945/pubmed" id="26555945" target="_blank">26555945</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25701373">
<a name="25701373"></a>Guethoff S, Stroeh K, Grinninger C, et al. De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation--8-year results. <i>J Heart Lung Transplant</i>. 2015;34(5):634-642. doi:10.1016/j.healun.2014.11.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/25701373/pubmed" id="25701373" target="_blank">25701373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29356560">
<a name="29356560"></a>Gupta N, Johnson SR, Moss J, McCormack FX. Reply to Yanagisawa: treatment of pulmonary lymphangioleiomyomatosis during pregnancy. <i>Am J Respir Crit Care Med</i>. 2018;197(11):1507-1508. doi:10.1164/rccm.201801-0043LE<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/29356560/pubmed" id="29356560" target="_blank">29356560</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15910380">
<a name="15910380"></a>Gupta P, Kaufman S, Fishbein TM. Sirolimus for solid organ transplantation in children. <i>Pediatr Transplant</i>. 2005;9(3):269-276. doi: 10.1111/j.1399-3046.2005.00305.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/15910380/pubmed" id="15910380" target="_blank">15910380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17919619">
<a name="17919619"></a>Gustafsson F, Ross HJ, Delgado MS, Bernabeo G, Delgado DH. Sirolimus-based immunosuppression after cardiac transplantation: predictors of recovery from calcineurin inhibitor-induced renal dysfunction. <i>J Heart Lung Transplant</i>. 2007;26(10):998-1003.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/17919619/pubmed" id="17919619" target="_blank">17919619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21445948">
<a name="21445948"></a>Hammill AM, Wentzel M, Gupta A, et.al. Sirolimus for the treatment of complicated vascular anomalies in children. <i>Pediatr Blood Cancer</i>. 2011;57:1018-1024.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/21445948/pubmed" id="21445948" target="_blank">21445948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16297793">
<a name="16297793"></a>Hunt J, Lerman M, Magee MJ, Dewey TM, Herbert M, Mack MJ. Improvement of renal dysfunction by conversion from calcineurin inhibitors to sirolimus after heart transplantation. <i>J Heart Lung Transplant</i>. 2005;24(11):1863-1867.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/16297793/pubmed" id="16297793" target="_blank">16297793</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21338459">
<a name="21338459"></a>Hymes LC, Warshaw BL. Five-year experience using sirolimus-based calcineurun inhibitor-free immunosuppression in pediatric renal transplantation.<i> Pediatric Transplantation</i>. 2011;15:437-441.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/21338459/pubmed" id="21338459" target="_blank">21338459</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16048606">
<a name="16048606"></a>Hymes LC, Warshaw BL. Sirolimus in pediatric patients: results in the first 6 months post-renal transplant. <i>Pediatric Transplantation</i>. 2005;9:520-522.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/16048606/pubmed" id="16048606" target="_blank">16048606</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18282210">
<a name="18282210"></a>Hymes LC, Warshaw BL, Amaral SG, et.al. Tacrolimus withdrawal and conversion to sirolimus at three months post-pediatric renal transplantation. <i>Pediatr Transplantation</i>. 2008;12:773-777.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/18282210/pubmed" id="18282210" target="_blank">18282210</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23415313">
<a name="23415313"></a>Kaczmarek I, Zaruba MM, Beiras-Fernandez A, et al. Tacrolimus with mycophenolate mofetil or sirolimus compared with calcineurin inhibitor-free immunosuppression (sirolimus/mycophenolate mofetil) after heart transplantation: 5-year results. <i>J Heart Lung Transplant</i>. 2013;32(3):277-284. doi:10.1016/j.healun.2012.11.028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/23415313/pubmed" id="23415313" target="_blank">23415313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10963197">
<a name="10963197"></a>Kahan BD, “Efficacy of Sirolimus Compared With Azathioprine for Reduction of Acute Renal Allograft Rejection: A Randomised Multicentre Study. The Rapamune US Study Group,” <i>Lancet</i>, 2000, 356(9225):194-202.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/10963197/pubmed" id="10963197" target="_blank">10963197</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDIGO.1">
<a name="KDIGO.1"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. <i>Am J Transplant.</i> 2009;9 (Suppl 3):S1-155. doi:10.1111/j.1600-6143.2009.02834.x</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12792493">
<a name="12792493"></a>King-Biggs MB, Dunitz JM, Park SJ, Kay Savik S, Hertz MI. Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation. <i>Transplantation</i>. 2003;75(9):1437-1443.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/12792493/pubmed" id="12792493" target="_blank">12792493</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32603426">
<a name="32603426"></a>Kornblit B, Storer BE, Andersen NS, et al. Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen-mismatched donors. <i>Blood</i>. 2020;136(13):1499-1506. doi:10.1182/blood.2020005338<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/32603426/pubmed" id="32603426" target="_blank">32603426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16364861">
<a name="16364861"></a>Kushwaha SS, Khalpey Z, Frantz RP, et al, “Sirolimus in Cardiac Transplantation: Use as a Primary Immunosuppressant in Calcineurin Inhibitor-Induced Nephrotoxicity,” <i>J Heart Lung Transplant</i>, 2005, 24(12):2129-36.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/16364861/pubmed" id="16364861" target="_blank">16364861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26932352">
<a name="26932352"></a>Levitsky J, O'Leary JG, Asrani S, et al. Protecting the kidney in liver transplant recipients: practice-based recommendations from the American Society of Transplantation liver and intestine community of practice. <i>Am J Transplant</i>. 2016;16(9):2532-2544. doi:10.1111/ajt.13765<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/26932352/pubmed" id="26932352" target="_blank">26932352</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15701435">
<a name="15701435"></a>Lobach NE, Pollock-Barziv SM, West LJ, et al, "Sirolimus Immunosuppression in Pediatric Heart Transplant Recipients: A Single-Center Experience," <i>J Heart Lung Transplant</i>, 2005, 24(2):184-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/15701435/pubmed" id="15701435" target="_blank">15701435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34402354">
<a name="34402354"></a>Longhitano E, Zirino F, Calabrese V, et al. Commonly used immunosuppressive drugs for kidney diseases and pregnancy: focus on open questions. <i>Expert Rev Clin Pharmacol</i>. 2021;14(11):1321-1323. doi:10.1080/17512433.2021.1968831<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/34402354/pubmed" id="34402354" target="_blank">34402354</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25420815">
<a name="25420815"></a>López LF, Martínez CJ, Castañeda DA, Hernández AC, Pérez HC, Lozano E. Pregnancy and kidney transplantation, triple hazard? Current concepts and algorithm for approach of preconception and perinatal care of the patient with kidney transplantation. <i>Transplant Proc</i>. 2014;46(9):3027-3031. doi:10.1016/j.transproceed.2014.07.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/25420815/pubmed" id="25420815" target="_blank">25420815</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12742978">
<a name="12742978"></a>Mancini D, Pinney S, Burkhoff D, et al, “Use of Rapamycin Slows Progression of Cardiac Transplantation Vasculopathy,” <i>Circulation</i>, 2003, 108(1):48-53.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/12742978/pubmed" id="12742978" target="_blank">12742978</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20214748">
<a name="20214748"></a>Matthews KL, Gossett J, Vande Kappelle P, et.al. Indications, tolerance and complications of a sirolimus and calineurin inhibitor immunosuppression regimen: intermediate experience in pediatric heart transplantation recipients. <i>Pediatric Transplantation</i>. 2010;14:402-408.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/20214748/pubmed" id="20214748" target="_blank">20214748</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11510015">
<a name="11510015"></a>McAlister VC, Peltekian KM, Malatjalian DA, et al. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus. <i>Liver Transpl</i>. 2001;7(8):701-708. doi:10.1053/jlts.2001.26510<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/11510015/pubmed" id="11510015" target="_blank">11510015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21410393">
<a name="21410393"></a>McCormack FX, Inoue Y, Moss J, et al, “Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis,” <i>N Engl J Med</i>, 2011, 364(17):1595-606.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/21410393/pubmed" id="21410393" target="_blank">21410393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27628078">
<a name="27628078"></a>McCormack FX, Gupta N, Finlay GR, et al; ATS/JRS Committee on Lymphangioleiomyomatosis. Official American Thoracic Society/Japanese Respiratory Society clinical practice guidelines: lymphangioleiomyomatosis diagnosis and management. <i>Am J Respir Crit Care Med</i>. 2016;194(6):748-761. doi:10.1164/rccm.201607-1384ST<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/27628078/pubmed" id="27628078" target="_blank">27628078</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11213073">
<a name="11213073"></a>McDonald AS, “A Worldwide, Phase III, Randomized, Controlled, Safety and Efficacy Study of a Sirolimus/Cyclosporine Regimen for Prevention of Acute Rejection in Recipients of Primary Mismatched Renal Allografts. RAPAMUNE Global Study Group,” <i>Transplantation</i>, 2001, 71(2):271-80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/11213073/pubmed" id="11213073" target="_blank">11213073</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17100699">
<a name="17100699"></a>Mehrabi A, Fonouni H, Kashfi A, et al. The role and value of sirolimus administration in kidney and liver transplantation. <i>Clin Transplant</i>. 2006;20(suppl 17):S30-S43. doi:10.1111/j.1399-0012.2006.00598.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/17100699/pubmed" id="17100699" target="_blank">17100699</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28230639">
<a name="28230639"></a>Nashan B. mTOR inhibition and clinical transplantation: liver. <i>Transplantation</i>. 2018;102(2S):S19-S26. doi:10.1097/TP.0000000000001690<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/28230639/pubmed" id="28230639" target="_blank">28230639</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36032031">
<a name="36032031"></a>Nelson J, Alvey N, Bowman L, et al. Consensus recommendations for use of maintenance immunosuppression in solid organ transplantation: endorsed by the American College of Clinical Pharmacy, American Society of Transplantation, and the International Society for Heart and Lung Transplantation. <i>Pharmacotherapy</i>. 2022;42(8):599-633. doi:10.1002/phar.2716<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/36032031/pubmed" id="36032031" target="_blank">36032031</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31338346">
<a name="31338346"></a>Park H, Chang CS, Choi SJ, Oh SY, Roh CR. Sirolimus therapy for fetal cardiac rhabdomyoma in a pregnant woman with tuberous sclerosis. <i>Obstet Gynecol Sci</i>. 2019;62(4):280-284. doi:10.5468/ogs.2019.62.4.280<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/31338346/pubmed" id="31338346" target="_blank">31338346</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31738834">
<a name="31738834"></a>Pidala J, Hamadani M, Dawson P, et al. Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial. <i>Blood</i>. 2020;135(2):97-107. doi:10.1182/blood.2019003125<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/31738834/pubmed" id="31738834" target="_blank">31738834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31742705">
<a name="31742705"></a>Pluym ID, Sklansky M, Wu JY, et al. Fetal cardiac rhabdomyomas treated with maternal sirolimus. <i>Prenat Diagn</i>. 2020;40(3):358-364. doi:10.1002/pd.5613<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/31742705/pubmed" id="31742705" target="_blank">31742705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34683097">
<a name="34683097"></a>Ponticelli C, Zaina B, Moroni G. Planned pregnancy in kidney transplantation. A calculated risk. <i>J Pers Med</i>. 2021;11(10):956. doi:10.3390/jpm11100956<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/34683097/pubmed" id="34683097" target="_blank">34683097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18025531">
<a name="18025531"></a>Raichlin E, Bae JH, Khalpey Z, et al, “Conversion to Sirolimus as Primary Immunosuppression Attenuates the Progression of Allograft Vasculopathy After Cardiac Transplantation,” <i>Circulation</i>, 2007, 116(23):2726-33.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/18025531/pubmed" id="18025531" target="_blank">18025531</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17713429">
<a name="17713429"></a>Raichlin E, Khalpey Z, Kremers W, et al, “Replacement of Calcineurin-Inhibitors With Sirolimus as Primary Immunosuppression in Stable Cardiac Transplant Recipients,” <i>Transplantation</i>, 2007, 84(4):467-74.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/17713429/pubmed" id="17713429" target="_blank">17713429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rapamune.1">
<a name="Rapamune.1"></a>Rapamune (sirolimus) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals LLC; August 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31248843">
<a name="31248843"></a>Sandmaier BM, Kornblit B, Storer BE, et al. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. <i>Lancet</i>
<i>Haematol</i>. 2019;6(8):e409-e418. doi:10.1016/S2352-3026(19)30088-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/31248843/pubmed" id="31248843" target="_blank">31248843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17711553">
<a name="17711553"></a>Sarwal M and Pascual J, "Immunosuppression Minimization in Pediatric Transplantation," <i>Am J Transplant</i>, 2007, 7(10):2227-35.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/17711553/pubmed" id="17711553" target="_blank">17711553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19155978">
<a name="19155978"></a>Schena FP, Pascoe MD, Alberu J, et al; Sirolimus CONVERT Trial Study Group. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. <i>Transplantation</i>. 2009;87(2):233-422. doi:10.1097/TP.0b013e3181927a41<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/19155978/pubmed" id="19155978" target="_blank">19155978</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15084173">
<a name="15084173"></a>Schubert M, Venkataramanan R, Holt DW, et al, "Pharmacokinetics of Sirolimus and Tacrolimus in Pediatric Transplant Patients," <i>Am J Transplant</i>, 2004, 4(5):767-73.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/15084173/pubmed" id="15084173" target="_blank">15084173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23078784">
<a name="23078784"></a>Shayani S, Palmer J, Stiller T, et al. Thombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus/sirolimus-based graft-versus-host disease prophylaxis. <i>Biol Blood Marrow Transplant</i>. 2013;19:298-304. doi: 10.1016/j.bbmt.2012.10.006.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/23078784/pubmed" id="23078784" target="_blank">23078784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33731151">
<a name="33731151"></a>Shen L, Xu W, Gao J, et al. Pregnancy after the diagnosis of lymphangioleiomyomatosis (LAM). <i>Orphanet J Rare Dis</i>. 2021;16(1):133. doi:10.1186/s13023-021-01776-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/33731151/pubmed" id="33731151" target="_blank">33731151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17198262">
<a name="17198262"></a>Sifontis NM, Coscia LA, Constantinescu S, et al. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. <i>Transplantation</i>. 2006;82(12):1698-1702. doi: 10.1016/j.bbmt.2012.10.006.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/17198262/pubmed" id="17198262" target="_blank">17198262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11983543">
<a name="11983543"></a>Snell GI, Levvey BJ, Chin W, et al. Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment. <i>J Heart Lung Transplant</i>. 2002;21(5):540-546.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/11983543/pubmed" id="11983543" target="_blank">11983543</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19570961">
<a name="19570961"></a>Stacchiotti S, Marrari A, Tamborini E, et al, “Response to Imatinib Plus Sirolimus in Advanced Chordoma,” <i>Ann Oncol</i>, 2009, 20(11):1886-94.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/19570961/pubmed" id="19570961" target="_blank">19570961</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16029064">
<a name="16029064"></a>Stenton SB, Partovi N, and Ensom MH, “Sirolimus: The Evidence for Clinical Pharmacokinetic Monitoring,” <i>Clin Pharmacokinet</i>, 2005, 44(8):769-86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/16029064/pubmed" id="16029064" target="_blank">16029064</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23775875">
<a name="23775875"></a>Teperman L, Moonka D, Sebastian A, et al; Spare-the-Nephron Trial Liver Transplantation Study Group. Calcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial. <i>Liver Transpl</i>. 2013;19(7):675-689. doi:10.1002/lt.23658<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/23775875/pubmed" id="23775875" target="_blank">23775875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22207715">
<a name="22207715"></a>Topilsky Y, Hasin T, Raichlin E, et al, “Sirolimus as Primary Immunosuppression Attenuates Allograft Vasculopathy With Improved Late Survival and Decreased Cardiac Events After Cardiac Transplantation,” <i>Circulation</i>, 2012, 125(5):708-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/22207715/pubmed" id="22207715" target="_blank">22207715</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30549350">
<a name="30549350"></a>Vachon-Marceau C, Guerra V, Jaeggi E, Chau V, Ryan G, Van Mieghem T. In-utero treatment of large symptomatic rhabdomyoma with sirolimus. <i>Ultrasound Obstet Gynecol</i>. 2019;53(3):420-421. doi:10.1002/uog.20196<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/30549350/pubmed" id="30549350" target="_blank">30549350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37080658">
<a name="37080658"></a>Velleca A, Shullo MA, Dhital K, et al. The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients. <i>J Heart Lung Transplant</i>. 2023;42(5):e1-e141. doi:10.1016/j.healun.2022.10.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/37080658/pubmed" id="37080658" target="_blank">37080658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15797743">
<a name="15797743"></a>Villanueva J, Boukhamseen A, Bhorade SM. Successful use in lung transplantation of an immunosuppressive regimen aimed at reducing target blood levels of sirolimus and tacrolimus. <i>J Heart Lung Transplant</i>. 2005;24(4):421-425. doi:10.1016/j.healun.2004.01.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/15797743/pubmed" id="15797743" target="_blank">15797743</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20048174">
<a name="20048174"></a>Wagner AJ, Malinowska-Kolodziej I, Morgan JA, et al, “Clinical Activity of mTOR Inhibition With Sirolimus in Malignant Perivascular Epithelioid Cell Tumors: Targeting the Pathogenic Activation of mTORC1 in Tumors,” <i>J Clin Oncol</i>, 2010, 28(5):835-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/20048174/pubmed" id="20048174" target="_blank">20048174</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34638024">
<a name="34638024"></a>Wang C, Guan D, Li R, Bing Z, Yang Y, Yang K. Comparative efficacies of different immunotherapy regimens in recurrent implantation failure: a systematic review and network meta-analysis. <i>J Reprod Immunol</i>. 2021;148:103429. doi:10.1016/j.jri.2021.103429<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/34638024/pubmed" id="34638024" target="_blank">34638024</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24105455">
<a name="24105455"></a>Wang CH, Chung FT, Lin SM, et al. Adjuvant treatment with a mammalian target of rapamycin inhibitor, sirolimus, and steroids improves outcomes in patients with severe H1N1 pneumonia and acute respiratory failure. <i>Crit Care Med</i>. 2014;42(2):313-321. doi:10.1097/CCM.0b013e3182a2727d<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/24105455/pubmed" id="24105455" target="_blank">24105455</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16699448">
<a name="16699448"></a>Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. <i>Transplantation</i>. 2006;81(9):1234-1248.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/16699448/pubmed" id="16699448" target="_blank">16699448</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22776430">
<a name="22776430"></a>Zuckermann A, Keogh A, Crespo-Leiro MG, et al, “Randomized Controlled Trial of Sirolimus Conversion in Cardiac Transplant Recipients With Renal Insufficiency,” <i>Am J Transplant</i>, 2012, 12(9):2487-97.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sirolimus-conventional-drug-information/abstract-text/22776430/pubmed" id="22776430" target="_blank">22776430</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10329 Version 446.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
